Last reviewed · How we verify

NCT03788577

Impact of Oligonol to Cardiometabolic Risk and Muscular Health

Completed NA Last updated 14 April 2023
What this trial tests

NA trial testing Oligonol intake in Muscle Loss in 120 participants. Completed in 1 April 2020.

Timeline
4 December 2018
Primary endpoint
1 April 2020
1 April 2020

Quick facts

Lead sponsorNational Yang Ming Chiao Tung University
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposeother
Enrollment120
Start date4 December 2018
Primary completion1 April 2020
Estimated completion1 April 2020
Sites1 location across Taiwan

Drugs / interventions tested

Conditions studied

Sponsor

National Yang Ming Chiao Tung University

Who can join

50 and older, any sex, with Muscle Loss or Muscle Weakness. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This project will mainly focus on Middle and old-aged adults, and examine whether Cardiovascular and metabolic risks can be reduced. In the meanwhile, this project will develop strategies for improving muscle loss , muscle strength decline, and the quality life of the elderly.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Muscle Loss

Currently open trials in the same condition.

Other National Yang Ming Chiao Tung University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03788577.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing